Stratos Genomics, the Seattle-based developer of low-cost gene sequencing technology, said today it has has added Heiner Dreismann, the former CEO of Roche Molecular Diagnostics, to its board of directors. Dreismann, 57, is known for pushing for wide adoption of polymerase chain reaction technology as a basic research tool in the 1990s. Dreismann said in a statement that Stratos Genomics “has the potential to radically transform the molecular diagnostics industry.”
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
